AXIS Clinicals, a Clinical Research Organization, welcomes Dr. Keith Gallicano as a consultant as the Senior Advisor in Clinical & Scientific Affairs.
DILWORTH, MN, 1st March, 2021 – AXIS Clinicals added another member as part of the consultation team with the welcoming of Dr. Keith Gallicano as the Senior Advisor in Clinical and Scientific Affairs.
Keith Gallicano, Ph.D. (Chemistry) is a consultant in clinical pharmacology and biopharmaceutics with expertise in the areas of bioequivalence, drug-drug interactions, and pharmacokinetic, pharmacodynamic and clinical endpoint trial design and data analysis/interpretation.
“As part of the AXIS consultation team, Dr. Gallicano will be assisting our teams with study design and Phase 1 trials. His extensive and diverse background in clinical research will be essential for AXIS to continue to provide excellent solutions for sponsor needs.”, said Senior Vice President of Business Development – John Pottier
Dr. Gallicano brings over 32 years of experience in the pharmaceutical industry and an exceptionally diverse background including various positions in government (Senior Research Scientist, Health Canada), academia (Assistant Professor of Medicine, University of Ottawa; Adjunct Professor of Pharmacology and Therapeutics, University of British Columbia), the pharmaceutical manufacturing industry (Head, Clinical and Regulatory Affairs, Axar Laboratories, Inc.; Director, Biopharmaceutics, Watson Laboratories, Inc.) and the CRO service industry (Chief Scientific Officer, Novum Pharmaceutical Research Services; Vice President, Research and Development, Axelson Biopharma Research, Inc.; Scientific Director, CroMedica Prime and Prime Trials).